Compare UK prices. 40+ products · 22 retailers scored
PeptideClear UK

GLP-1 clinic (high-touch)

Juniper

Women's-focused weight management programme. Strong on menopause-aware care and women's metabolic dynamics.

POM: Prescription only medicine (POM). PeptideClear is a comparison and information service. We do not prescribe, dispense, or recommend medication for individuals. A qualified GMC-registered prescriber determines suitability after consultation.

Headline price

£195 to £295/mo

Regulated as

GPhC pharmacy + GMC prescribers

Delivery area

UK-wide

Best for

Best for end-to-end weight programme

Weak on

Programme cost is at the high end. Some users want a leaner, lower-cost pharmacy-direct route after stabilising.

What stands out

Useful pages on Juniper

Our verdict

Best women's-pitched programme in the UK. Menopause framing is the clearest in the segment.

Last reviewed 2026-05-10. PeptideClear earns a referral fee when readers click through and convert. Editorial criteria are documented in our methodology.

Ready to start?

Visit Juniper →

Affiliate link. No price difference for you.

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-07-03T12:00:00.000Z
Trust, Legal and Governance

PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.

Legal and Registration

Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.

Standards and Governance

Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.

Domain Continuity

Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.